Skip to search formSkip to main contentSkip to account menu

BB 882

Known as: BB-882 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2002
Review
2002
The recent clinical trials of lexipafant in the treatment of acute pancreatitis were undertaken with considerable optimism. It… 
Highly Cited
2001
Highly Cited
2001
BACKGROUND The role of cell adhesion molecules and transmigration of PMNs through the endothelial barrier is probably essential… 
Highly Cited
2000
Highly Cited
2000
Objective: To evaluate the safety and efficacy of the platelet‐activating factor receptor antagonist BB‐882 in the treatment of… 
Highly Cited
1999
Highly Cited
1999
Endothelial barrier dysfunction is a critical link in the development of tissue injury and organ dysfunction, via upregulation… 
1998
1998
Platelet-activating factor (PAF) may play a critical and primary role in the pathogenesis of acute pancreatitis and pancreatitis… 
1996
1996
Acute pancreatitis is associated with the development of pulmonary dysfunction in a number of patients. The aim of this study was… 
1996
1996
Objective: To assess the anti-inflammatory action of lexipafant (BB-882), a platelet activating factor antagonist, in an animal… 
Highly Cited
1994
Highly Cited
1994
The effect of a potent platelet‐activating factor (PAF) antagonist, BB‐882, on an experimental model of acute pancreatitis…